Describes the organization of the reorganization of drugs in the pharmaceutical company Wyeth, and is focused on solutions for: (1) to centralize decision-making in the drug and (2) Institute of numerical metrics - jointly affecting all R & D scientists - for the progression of compounds through the Wyeth pipeline. Key issues relating to the extent to which research activities can be evaluated using numerical metrics, the extent to which R & D can be structured as a process, and the extent to which the decision-making process should be centralized in commercial R & D activities.
Can be used in conjunction with HBS case 605-074 (GlaxoSmithKline: Reorganizing Drug Discovery (A)) to oppose the use of centralized and decentralized decision-making models in pharmaceutical R & D. "Hide
by Gary P. Pisano, All Rennella, Robert S. Huckman Source: Harvard Business School 25 pages. Publication Date: February 7, 2007. Prod. #: 607008-PDF-ENG
Related Case Solutions & Analyses:
Fat Debate on Big Food Unraveling Blogosphere Reactions
Kingdee in 2011: Stranding or Dormancy
Caesars Entertainment: CodeGreen
Red Hen Baking Company
Innovation Blueprint
Symantec vs. McAfee: Competing in the Consumer Anti-Virus Industry
Pfizers Virtual CIO (Abridged)
Digitas (A)
Bob Galvin and Motorola Inc. (A)
Pepsi’s Regeneration, 1990-93
